Latest news with #AMFGeneralRegulation
Business Wire
11-07-2025
- Business
- Business Wire
Number of Shares and Voting Rights of ADOCIA as of June 30 th, 2025
LYON, France--(BUSINESS WIRE)--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French 'Code de Commerce' and article 223-16 of the General Regulation of the French stock-market authorities (Autorité des Marchés Financiers, or 'AMF'), ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of June 30 th, 2025. * 192,300 free shares have been issued during the month in accordance with the plans detailed in section 5.1.5.2 of the 2024 Universal Registration Document, released on April 29, 2025. (1) The total number of theoretical voting rights is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. (2) The total number of exercisable voting rights is calculated without taking into account the shares with suspended voting rights, in this case, shares held by the Company in the context of a liquidity agreement. It is provided for the information of the public, in accordance with the AMF recommendation of July 17, 2007. About Adocia Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone ® technology for the development of new generation insulins and products combining different hormones; 2) AdOral ®, an oral peptide delivery technology; 3) AdoShell ®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel ®, a long-acting drug delivery platform. Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).
Business Wire
07-07-2025
- Business
- Business Wire
Sopra Steria: Weekly Disclosure of Transactions in Own Shares From June 30 th to July 4 th, 2025
PARIS--(BUSINESS WIRE)--Regulatory News: Pursuant to implementing Directive of Commission Regulation (EC) No. 596/2014 of 16 April 2014 on the abuses of market and in accordance with Article 241-4 of the AMF General Regulation, Sopra Steria Group (Paris:SOP) hereby discloses the transactions in its own shares carried out on 1 st July 2025: Trading day Type of transaction Number of shares Weighted average price (EUR) Total amount (EUR) 01/07/2025 Transfer 143,164 N/A N/A Expand Transfer outside a trading venue carried out under the delivery and final allotment, to the beneficiaries who meet all the conditions of the plan after application of the performance conditions, of the free performance shares of the plan LTI 2022 authorised by Sopra Steria's General Meeting of 26/05/2021 and decided on 1 st June 2022. Delivery date in accordance with the terms and conditions of the Plan (see pages 285-286 of the 2024 Universal Registration Document). Disclaimer This document is a free translation into English of the original French press release. It is not a binding document. In the event of a conflict in interpretation, reference should be made to the French version, which is the authentic text.
Business Wire
12-06-2025
- Business
- Business Wire
TotalEnergies SE: Information Concerning the Total Number of Voting Rights and Shares in the Share Capital as at May 31, 2025
PARIS--(BUSINESS WIRE)--Regulatory News: TotalEnergies SE (Paris:TTE) (LSE:TTE) (NYSE:TTE): Date Total number of shares Number of voting rights 2,270,057,201 2,270,057,201 2,202,098,593 Expand (1) In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all the shares to which voting rights are attached, including shares for which voting rights have been suspended. (2) Total number of exercisable voting rights, after deduction of 67,958,608 treasury shares.
Yahoo
12-06-2025
- Business
- Yahoo
TotalEnergies SE: Information Concerning the Total Number of Voting Rights and Shares in the Share Capital as at May 31, 2025
(Article L.233-8-II of the French Commercial Code and article 223-16 of the General Regulation of the AMF) PARIS, June 12, 2025--(BUSINESS WIRE)--Regulatory News: TotalEnergies SE (Paris:TTE) (LSE:TTE) (NYSE:TTE): Date Total number of shares Number of voting rights Theoretical (1) Exercisable (2) May 31, 2025 2,270,057,201 2,270,057,201 2,202,098,593 (1) In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all the shares to which voting rights are attached, including shares for which voting rights have been suspended. (2) Total number of exercisable voting rights, after deduction of 67,958,608 treasury shares. View source version on Contacts TotalEnergies SE
Yahoo
12-06-2025
- Business
- Yahoo
Number of Shares and Voting Rights of ADOCIA as of May 31st, 2025
LYON, France, June 12, 2025--(BUSINESS WIRE)--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF"), ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of May 31st, 2025. Month Date Total number of outstanding shares Total number of theoretical voting rights (1) Total number of exercisable voting rights (2) May 05/31/2025 18,087,690 20,213,633 20,168,948 (1) The total number of theoretical voting rights is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. (2) The total number of exercisable voting rights is calculated without taking into account the shares with suspended voting rights, in this case, shares held by the Company in the context of a liquidity agreement. It is provided for the information of the public, in accordance with the AMF recommendation of July 17, 2007. About Adocia Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone® technology for the development of new generation insulins and products combining different hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel®, a long-acting drug delivery platform. Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241). View source version on Contacts Adocia Olivier Soula CEOcontactinvestisseurs@ Tel: +33 4 72 610 Ulysse Communication Adocia Media and Investor Relations Bruno ArabianNicolas Entzadocia@ + 33 (0)6 87 88 47 26 Sign in to access your portfolio
